2020
Estimation in the Cox survival regression model with covariate measurement error and a changepoint
Agami S, Zucker DM, Spiegelman D. Estimation in the Cox survival regression model with covariate measurement error and a changepoint. Biometrical Journal 2020, 62: 1139-1163. PMID: 32003495, DOI: 10.1002/bimj.201800085.Peer-Reviewed Original ResearchConceptsSystolic blood pressure levelsChronic air pollution exposureCox survival regression modelFatal myocardial infarctionBlood pressure levelsCardiovascular disease deathsCox regression modelAir pollution exposureRegression modelsDisease deathsMyocardial infarctionRelative riskStandard Cox modelSurvival regression modelsCox modelPollution exposureSurvival endpointsCovariates of interest
2004
Inference for the Proportional Hazards Model with Misclassified Discrete‐Valued Covariates
Zucker DM, Spiegelman D. Inference for the Proportional Hazards Model with Misclassified Discrete‐Valued Covariates. Biometrics 2004, 60: 324-334. PMID: 15180657, DOI: 10.1111/j.0006-341x.2004.00176.x.Peer-Reviewed Original ResearchAssociation Between Low Birth Weight and Infant Mortality in Children Born to Human Immunodeficiency Virus 1-Infected Mothers in Tanzania
Wei R, Msamanga GI, Spiegelman D, Hertzmark E, Baylin A, Manji K, Fawzi WW. Association Between Low Birth Weight and Infant Mortality in Children Born to Human Immunodeficiency Virus 1-Infected Mothers in Tanzania. The Pediatric Infectious Disease Journal 2004, 23: 530-535. PMID: 15194834, DOI: 10.1097/01.inf.0000129691.42964.eb.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAnalysis of VarianceCohort StudiesConfidence IntervalsDeveloping CountriesFemaleHIV InfectionsHIV-1HumansIncidenceInfant MortalityInfant, Low Birth WeightInfant, NewbornInfectious Disease Transmission, VerticalMalePregnancyPregnancy Complications, InfectiousPregnancy OutcomeProportional Hazards ModelsRisk FactorsSex DistributionSurvival AnalysisTanzaniaConceptsLow birth weightBirth weightHIV statusHIV transmissionInfant mortalityCox proportional hazards modelHuman immunodeficiency virus-1Child's HIV statusPediatric HIV infectionHuman immunodeficiency virusRisk of mortalityImmunodeficiency virus-1Proportional hazards modelWeeks of ageAntiretroviral treatmentHIV infectionImmunodeficiency virusNeonatal mortalityPositive infantsPregnant womenPostneonatal mortalityHazards modelMortalityInfantsVirus 1
2002
Weight Loss and Survival in HIV-Positive Patients in the Era of Highly Active Antiretroviral Therapy
Tang AM, Forrester J, Spiegelman D, Knox TA, Tchetgen E, Gorbach SL. Weight Loss and Survival in HIV-Positive Patients in the Era of Highly Active Antiretroviral Therapy. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2002, 31: 230-236. PMID: 12394802, DOI: 10.1097/01.qai.0000026514.98625.8f.Peer-Reviewed Original ResearchConceptsActive antiretroviral therapyWeight lossAntiretroviral therapyHAART useIndependent predictorsPrevious visitHighly Active Antiretroviral TherapyHealthy Living StudyCD4 cell countHIV-positive patientsHIV-positive participantsBody mass indexStrong independent predictorFurther prognostic valueProportional hazards modelBioelectrical impedance analysisFour- to sixfold increaseImportant comorbidityMass indexPrognostic valuePotential confoundersRelative riskStudy populationLiving StudyHazards model
1999
Effects of Long‐Acting Versus Short‐Acting Calcium Channel Blockers Among Older Survivors of Acute Myocardial Infarction
Gillman M, Ross‐Degnan D, McLaughlin T, Gao X, Spiegelman D, Hertzmark E, Goldman L, Soumerai S. Effects of Long‐Acting Versus Short‐Acting Calcium Channel Blockers Among Older Survivors of Acute Myocardial Infarction. Journal Of The American Geriatrics Society 1999, 47: 512-517. PMID: 10323641, DOI: 10.1111/j.1532-5415.1999.tb02562.x.Peer-Reviewed Original ResearchConceptsCalcium channel blockersAcute myocardial infarctionShort-acting calcium channel blockersCardiac rehospitalizationMyocardial infarctionChannel blockersRelative riskOlder survivorsActing calcium channel blockerSeparate Cox regression modelsDihydropyridine calcium channel blockerRetrospective cohort studyCoronary heart diseaseDrug claims dataCox regression modelDrug benefit programCause mortalityClinical characteristicsCohort studyEligible subjectsRehospitalization ratesAdverse outcomesHeart diseaseOutcome measuresRehospitalizationA randomized trial of vitamin A supplements in relation to mortality among human immunodeficiency virus-infected and uninfected children in Tanzania
FAWZI W, MBISE R, HERTZMARK E, FATAKI M, HERRERA M, NDOSSI G, SPIEGELMAN D. A randomized trial of vitamin A supplements in relation to mortality among human immunodeficiency virus-infected and uninfected children in Tanzania. The Pediatric Infectious Disease Journal 1999, 18: 127-133. PMID: 10048684, DOI: 10.1097/00006454-199902000-00009.Peer-Reviewed Original ResearchConceptsUninfected childrenCause mortalityChildren ages 6 monthsMortality of HIVTrial of vitaminPlacebo-controlled trialDiarrhea-related deathsAge 6 monthsWestern blot testMonths of ageEnzyme-linked immunosorbentLow-cost interventionChildren 58HIV antibodiesHospital dischargeHIV infectionHIV statusPositive childrenStandard treatmentMean durationAntigen assaysFurther dosesHuman immunodeficiencyClinical signsNeutralization assays
1997
Adverse outcomes of underuse of beta-blockers in elderly survivors of acute myocardial infarction.
Soumerai SB, McLaughlin TJ, Spiegelman D, Hertzmark E, Thibault G, Goldman L. Adverse outcomes of underuse of beta-blockers in elderly survivors of acute myocardial infarction. JAMA 1997, 277: 115-21. PMID: 8990335, DOI: 10.1001/jama.277.2.115.Peer-Reviewed Original ResearchConceptsCalcium channel blockersCalcium channel blocker useAdverse outcomesChannel blockersBlocker useEligible patientsMyocardial infarctionRelative riskMortality rateAcute myocardial infarction survivorsBaseline risk variablesCardiac hospital readmissionsElderly AMI survivorsBeta-blocker therapyBeta-blocker usePredictors of survivalRisk of deathRetrospective cohort designAcute myocardial infarctionDemonstrable adverse effectsMyocardial infarction survivorsPrescription drug coverageMeasurable adverse outcomesBeta blockersElderly patients